| 001 | 153422 | ||
| 005 | 20230915094021.0 | ||
| 024 | 7 | _ | |a 10.5414/NP301278 |2 doi |
| 037 | _ | _ | |a DZNE-2020-01419 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Riemenschneider, Markus J. |b 0 |
| 245 | _ | _ | |a Quality assurance in neuropathology: Experiences from the round robin trials on IDH mutation and MGMT promoter methylation testing launched by the Quality Assurance Initiative Pathology (QuIP) in 2018 and 2019 |
| 260 | _ | _ | |a Deisenhofen, München |c 2020 |b Dustri-Verl. |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1606486947_22902 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 520 | _ | _ | |a We here report on the first neuropathological round robin trials initiated by the Quality Assurance Initiative Pathology (QuIP) in Germany in the years 2018 and 2019. Testing services as external laboratory controls were offered for IDH1-R132H immunohistochemistry in 2018 followed by a molecular trial for IDH1 and IDH2 mutations in 2019 including the rare mutational variants. Also in 2019, a trial on MGMT promoter methylation testing was offered. On a national scale, trial offers were well received with around 40 participating institutions. The international announcement of the molecular IDH1/IDH2 mutational trial achieved only moderate European outspread. Success rates in all three trials were excellent (IDH1-R132H immunohistochemistry 2018: 94%, 18 out of 20 possible points required; IDH1/IDH2 mutational status 2019: 100%, 19 out of 20 possible points required; MGMT promoter methylation 2019: 94%, 19 out of 20 possible points required) indicating that quality standards are high in the broad majority of the institutions. Trial participation also involved filling in a questionnaire asking for background information on local testing procedures. We here present a first assessment of the information collected providing unique insights in the landscape of molecular testing in neuropathology. Derived from this information we identify future challenges and provide an outlook on the development of quality assurance in the field of neuropathology. |
| 536 | _ | _ | |a 345 - Population Studies and Genetics (POF3-345) |0 G:(DE-HGF)POF3-345 |c POF3-345 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef |
| 700 | 1 | _ | |a Fischer, Josephine |b 1 |
| 700 | 1 | _ | |a Grassow-Narlik, Maja |b 2 |
| 700 | 1 | _ | |a Mawrin, Christian |b 3 |
| 700 | 1 | _ | |a Deimling, Andreas von |b 4 |
| 700 | 1 | _ | |a Pietsch, Torsten |0 P:(DE-2719)2812617 |b 5 |u dzne |
| 700 | 1 | _ | |a Reifenberger, Guido |b 6 |
| 700 | 1 | _ | |a Mueller, Wolf C. |b 7 |
| 700 | 1 | _ | |a Sommer, Clemens J. |b 8 |
| 700 | 1 | _ | |a Dietel, Manfred |b 9 |
| 700 | 1 | _ | |a Zoubaa, Saida |b 10 |
| 700 | 1 | _ | |a Lorenz, Julia |0 P:(DE-HGF)0 |b 11 |e Corresponding author |
| 700 | 1 | _ | |a Rothhammer-Hampl, Tanja |0 P:(DE-HGF)0 |b 12 |e Corresponding author |
| 773 | _ | _ | |a 10.5414/NP301278 |g Vol. 39, no. 09, p. 203 - 211 |0 PERI:(DE-600)2007408-6 |n 09 |p 203 - 211 |t Clinical neuropathology |v 39 |y 2020 |x 0722-5091 |
| 909 | C | O | |o oai:pub.dzne.de:153422 |p VDB |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 5 |6 P:(DE-2719)2812617 |
| 913 | 1 | _ | |a DE-HGF |b Forschungsbereich Gesundheit |l Erkrankungen des Nervensystems |1 G:(DE-HGF)POF3-340 |0 G:(DE-HGF)POF3-345 |2 G:(DE-HGF)POF3-300 |v Population Studies and Genetics |x 0 |
| 914 | 1 | _ | |y 2020 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2020-08-21 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2020-08-21 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b CLIN NEUROPATHOL : 2019 |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0320 |2 StatID |b PubMed Central |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |d 2021-01-27 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2021-01-27 |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |d 2021-01-27 |
| 920 | 1 | _ | |0 I:(DE-2719)1011009 |k Brainbank Unit Bonn |l Brainbank Unit Bonn |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-2719)1011009 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|
guest ::